Kraft M, Kraft K, Grtner S, Mayerle J, Simon P, Weber E, Schtte K, Stieler J, Koula-Jenik H, Holzhauer P, Grber U, Engel G, Mller C, Feng YS, Aghdassi A, Nitsche C, Malfertheiner P, Patrzyk M, Kohlmann T, Lerch MM
12 Most high-income countries do not currently subsidise GLP-1 RA for this indication, with concerns about the budget impacts and cost-effectiveness of these medicines 10, 11 particularly given the high prevalence of the condition (one-third of Australian adults have obesity) 33 and need for long-term therapy to maintain weight loss
391 However, more research and direct evidence are needed for MG intervention
Am J Hematol 95:E83E86
This is a natural ingredient works slower